E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

May 7th 2020
press releases

Immutep to Present at Virtual Healthcare Investor Conference

May 1st 2020
press releases

Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

April 30th 2020
press releases
more

Investor updates

Investor updates.

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates
more

Analyst reports

Analyst reports.

goetzpartners securities - First in class opening the cancer immune throttle

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 14th 2020
analyst reports

Maxim - Data From TACTI-002 Continues to be Positive, Activity In the Space Bodes Well for Immutep

April 29th 2020
analyst reports

Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

March 27th 2020
analyst reports
more